government & private funding resources for COVID-19 related products, medical technologies and drugs
May 14, 2020
Government to Growth
Government to Growth (G2G) is led by Liz Powell, Esq., MPH, and includes a team of government affairs professionals who help startups, businesses and non-profits effectively navigate non-dilutive federal funding opportunities. With a specialty focus on life sciences, G2G tracks grants on a daily basis and produces a monthly GBG Report listing all bioscience funding opportunities.
Biomedical Advanced Research and Development Authority
Biomedical Advanced Research and Development Authority (BARDA) is investing in an array of medical countermeasures to diagnose, treat, or protect against the 2019 novel coronavirus. To spur innovation, BARDA has issued its business-friendly, streamlined Easy Broad Agency Announcement (EZ-BAA) to support a number of new medical countermeasures to fight the COVID-19 outbreak.
NIH Technology Accelerator Challenge
NIBIB is offering $1 million in prizes to reward and spur the development of platform concepts and prototypes of non-invasive, multiplexed diagnostic technologies for sickle cell disease, malaria, and anemia, diseases with high global and public health impact.
Brex
Brex has published a guide that explores the different sources of funding available to biotech startups and their relative merits, and how you should best utilize that funding at each stage of your research.
Recent News
- BD Launches Landmark Cell Analyzer Featuring Breakthrough Spectral and Real-Time Cell Imaging Technologies
- KyphoLift Debuts at ISMRM 2025: Transforming Patient Positioning for Safer, More Accurate Imaging
- Kelvyn Cullimore: An Unfair Penalty on Life-Saving Pills
- Merit Medical Announces Health Canada Approval of the WRAPSODY® Cell-Impermeable Endoprosthesis
- Merit Medical Releases 12-Month Efficacy Results for the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY® Arteriovenous Efficacy (WAVE) Trial
- Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology
